Elanco Animal Health (ELAN) Reports In-Line Q4 EPS; Confirms Guidance

Elanco Animal Health (NYSE: ELAN) reported Q4 EPS of $0.23, in-line with the analyst estimate of $0.23. Revenue for the quarter came in at $787 million versus the consensus estimate of $791.5 million.

GUIDANCE:

Confirmed financial guidance for the full year 2020, with total revenue in the range of $3.05 billion - $3.11 billion, Core Revenue in the range of $3.00 billion - $3.06 billion, and EPS in the range of $0.04 - $0.16 (reported), or $1.09 to $1.16 (adjusted). Guidance does not contemplate contributions from Bayer animal health or additional financing elements.

For earnings history and earnings-related data on Elanco Animal Health (ELAN) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Bassett Furniture Industries (BSET) Tops Q2 EPS by 1c, Misses on Revenue
• Columbus McKinnon names John Linker as CFO, reaffirms FY2027 guidance